Atea Pharmaceuticals, Inc. (AVIR) NASDAQ
5.74
+0.04(+0.70%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.74
+0.04(+0.70%)
Currency In USD
| Previous Close | 5.7 |
| Open | 5.78 |
| Day High | 5.81 |
| Day Low | 5.61 |
| 52-Week High | 6.45 |
| 52-Week Low | 2.46 |
| Volume | 418,853 |
| Average Volume | 550,570 |
| Market Cap | 457.32M |
| PE | -2.96 |
| EPS | -1.94 |
| Moving Average 50 Days | 5.29 |
| Moving Average 200 Days | 3.84 |
| Change | 0.04 |
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
GlobeNewswire Inc.
Feb 26, 2026 12:00 PM GMT
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral disease
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026